IPO - NAYA Biosciences, Inc.

Form Type: 424B4

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225002078

Filing Summary: NAYA Biosciences, Inc. is conducting an initial public offering (IPO) for an aggregate of 13,615,171 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at an assumed public offering price of $0.70 per unit. The offering also includes 11,003,571 pre-funded warrants. The warrants will be exercisable for five years at an exercise price equal to 100% of the public offering price. The public offering is being managed by Maxim Group LLC as the lead placement agent. The company has outlined plans for the use of proceeds, including funding clinical trials, debt obligations, and other corporate purposes. The final transaction completion is expected by January 14, 2025, and the last reported sale price was $0.50 per share prior to the offering. The company’s common stock is traded on the Nasdaq under the symbol 'NAYA'.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-08

Corporate Action: Ipo

Type: New

Accession Number: 000149315225001437

Filing Summary: NAYA Biosciences, Inc. is filing an Amendment No. 2 to Form S-1 for a registration statement under the Securities Act of 1933. The company aims to sell up to 14,942,529 Units, each consisting of one share of common stock and one warrant to purchase one share of common stock at an assumed public offering price of $0.87 per Unit. These securities will be offered on a continuous basis after the registration statement becomes effective. The Units will not be certifiably issued as standalone securities but will include securities that are immediately separable. The prospectus details the company’s operations, including its focus on oncology, autoimmune diseases, and fertility solutions, leveraging a hub-and-spoke model for efficient asset development and commercialization. Additional notable aspects include NAYA's recent transition from INVO Bioscience and the integration of its therapeutic and fertility businesses for enhanced shareholder value. The company is classified as a smaller reporting company under SEC guidelines, and this offering is highly speculative with associated risks.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-07

Corporate Action: Ipo

Type: New

Accession Number: 000149315225001123

Filing Summary: NAYA Biosciences, Inc. is filing an amendment to its registration statement to offer up to $13,000,000 of units in an initial public offering. Each unit consists of one share of common stock or one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, all at an assumed public offering price of $0.87 per unit. The offering follows a strategic acquisition aimed at combining their commercial-stage fertility business with clinical-stage therapeutic assets in oncology and autoimmune diseases. The document outlines the use of proceeds, a detailed risk assessment, and the corporate history of NAYA, which was formed in 2007 and previously known as INVO Bioscience. The company operates under a hub-and-spoke model for managing its resources and subsidiaries effectively, enhancing the potential for value creation for shareholders. Additionally, it provides a brief overview of its clinical pipeline and other operational aspects.

Document Link: View Document